Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Top Innovation Stocks Surge: PRSO, SYTA, SAVE, ISPC, GRI, BIVI – Must-Watch Stocks This Week

Top Innovation Stocks Surge: PRSO, SYTA, SAVE, ISPC, GRI, BIVI - Must-Watch Stocks This Week

Several tech and innovation-driven companies are making waves in the stock market, with seeing significant investor interest driven by strong market trends and groundbreaking innovations in sectors such as military, telecommunications, biosciences, and aviation etc.

Peraso Inc. (NASDAQ: PRSO) has seen a significant rise, closing at $1.75 on Friday, up 28.67% over the past month, with an upward trending chart. The company is revolutionizing military communication through its advanced millimeter wave (mmWave) technology and steerable beam capabilities, which offer enhanced signal strength, security, and efficiency. Peraso's technology is crucial for military applications, enabling secure, long-range communication for drones and ground vehicles while improving mission coordination and targeting accuracy. With its future-proof design and 5G compatibility, Peraso is positioned to transform next-generation military communication systems.

Here are 5 other companies to Watch this week.

Siyata Mobile Inc. (Nasdaq: SYTA) has announced that its new SD7 Ultra series 5G mission-critical push-to-talk (MCPTT) cellular radios will be available on T-Mobile's extensive 5G network, providing first responders with reliable, nationwide radio communications. These devices, designed for public safety, will enhance operational awareness and improve emergency response times, ensuring critical situations are managed more effectively.

Struggling carrier Spirit Airlines (NASDAQ: SAVE) saw its stock surge 35% in premarket trading to $1.99 after receiving an extension on its debt refinancing deadline. The airline, which faced a Monday deadline to refinance over $1.1 billion in debt, announced in a securities filing that the deadline has been pushed to late December. Additionally, Spirit disclosed it has fully utilized its $300 million credit line, raising speculation about a potential takeover in the near future. 

iSpecimen Inc. (NASDAQ: ISPC), a technology-driven company revolutionizing the biospecimen procurement process through its iSpecimen Marketplace platform, is seeing unusual premarket activity today despite no specific news announcements. The company, which connects life science researchers with necessary human biofluids, tissues, and living cells, recently filed a prospectus for the offer and sale of up to 1.2 million shares of common stock and pre-funded warrants to purchase an additional 1.2 million shares. This unusual trading activity has sparked speculation, making it a stock to watch closely. 

GRI Bio (NASDAQ: GRI) has unveiled encouraging preclinical data highlighting the effectiveness of its lead drug candidate, GRI-0621, in targeting Idiopathic Pulmonary Fibrosis (IPF). The data demonstrate that GRI-0621 successfully inhibits invariant Natural Killer T (iNKT) cell activity, which plays a significant role in the inflammatory and fibrotic processes associated with IPF. By reducing both inflammation and fibrosis, GRI-0621 shows potential as a therapeutic option for this progressive lung disease. The company is advancing its Phase 2a biomarker study, with interim results anticipated in Q4 2024 and topline data expected in early 2025, marking a key step forward in the development of this promising treatment for IPF. 

BioVie Inc. (NASDAQ: BIVI) has received a Notice of Allowance from the Japan Patent Office for its patent application covering a novel liquid formulation of terlipressin, which offers a significant advantage with its 24-month room-temperature stability. This patent expands BioVie’s intellectual property portfolio, adding to existing protections in the United States, India, and Chile, with applications pending in eight additional markets. The liquid formulation is designed to treat patients with cirrhosis and ascites, particularly in home-care settings, enhancing its potential for widespread use in managing advanced liver disease. 

As these companies continue to capture investor attention with cutting-edge technologies and market-shifting innovations, their stocks are positioned for growth. Peraso Inc. (NASDAQ: PRSO) has seen a 28.67% rise over the past month, driven by advancements in technology poised to transform military communications. Other companies, including Siyata Mobile Inc. (NASDAQ: SYTA), Spirit Airlines (NASDAQ: SAVE), iSpecimen Inc. (NASDAQ: ISPC), GRI Bio (NASDAQ: GRI), and BioVie Inc. (NASDAQ: BIVI), are also gaining traction as they disrupt their respective industries.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.